EHR

Nabla Named to the 2025 New York Digital Health 100 by Digital Health New York (DHNY)

DH100 recognizes those companies that have helped make New York the capital of healthcare innovation NEW YORK, Feb. 11, 2025…

10 months ago

LogicMark Launches Next Generation of Guardian Alert 911 Plus Technology

Best-selling personal emergency response device is newly enhanced with fall detection, and a modern, sleek designLOUISVILLE, Ky., Feb. 11, 2025…

10 months ago

Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium

Flatiron’s high-quality real-world data and innovative artificial intelligence-based extraction are generating novel learnings on treatment safety and patterns for people…

11 months ago

Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology Genitourinary Cancers Symposium

Flatiron’s high-quality real-world data and innovative artificial intelligence-based extraction are generating novel learnings on treatment safety and patterns for people…

11 months ago

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic SuiteGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx…

11 months ago

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic SuiteGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx…

11 months ago

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis

Illustrative photo Boehringer Ingelheim Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was…

11 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in…

11 months ago

CereCore Achieves Outstanding 2025 KLAS Rating in Managed IT Services

CereCore earns top ratings from clients, outperforms in loyalty pillar NASHVILLE, Tenn., Feb. 7, 2025 /PRNewswire/ -- CereCore®, a leading provider…

11 months ago